Evaluation of Immediate Release Tablet
NCT02808741
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Invasive Aspergillosis
Interventions
DRUG:
F901318 SDD
DRUG:
F901318 IR
DRUG:
F901318 IR Fasting
DRUG:
F901318 IR Fed
Sponsor
F2G Ltd
Collaborators
[object Object]